CA2792036A1 - Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid - Google Patents

Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid Download PDF

Info

Publication number
CA2792036A1
CA2792036A1 CA2792036A CA2792036A CA2792036A1 CA 2792036 A1 CA2792036 A1 CA 2792036A1 CA 2792036 A CA2792036 A CA 2792036A CA 2792036 A CA2792036 A CA 2792036A CA 2792036 A1 CA2792036 A1 CA 2792036A1
Authority
CA
Canada
Prior art keywords
febuxostat
crystalline form
ketone
reaction mixture
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2792036A
Other languages
English (en)
French (fr)
Inventor
Sarbjot Singh Sokhi
Asok Nath
Nitin Tandon
Mohan Prasad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2792036A1 publication Critical patent/CA2792036A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2792036A 2010-03-04 2011-02-24 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid Abandoned CA2792036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN488/DEL/2010 2010-03-04
IN488DE2010 2010-03-04
PCT/IB2011/050785 WO2011107911A1 (en) 2010-03-04 2011-02-24 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

Publications (1)

Publication Number Publication Date
CA2792036A1 true CA2792036A1 (en) 2011-09-09

Family

ID=43881251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792036A Abandoned CA2792036A1 (en) 2010-03-04 2011-02-24 Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

Country Status (4)

Country Link
EP (1) EP2542540A1 (de)
AU (1) AU2011222462A1 (de)
CA (1) CA2792036A1 (de)
WO (1) WO2011107911A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038971A2 (en) 2010-09-24 2012-03-29 Hetero Research Foundation Novel polymorphs of febuxostat
WO2012168948A2 (en) 2011-06-06 2012-12-13 Hetero Research Foundation Process for febuxostat
EP2780335B1 (de) 2011-11-15 2019-04-10 Mylan Laboratories, Limited Verbessertes verfahren zur herstellung von febuxostatpolymorphen
CZ27857U1 (cs) 2014-12-12 2015-02-23 Zentiva, K.S. Formulace obsahující tuhý roztok febuxostatu

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142494T1 (de) 1990-11-30 1996-09-15 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
DE122010000013I1 (de) 1998-06-19 2010-07-08 Teijin Pharma Ltd Polymorphe modifikationen der 2-(3-cyano-4-isobutylphenyl)-4-methyl-5-thiazol-carbonsäure und verfahren zu ihrer herstellung
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
JP5193863B2 (ja) 2006-06-23 2013-05-08 帝人ファーマ株式会社 ２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法
CN101139325B (zh) 2006-09-07 2010-05-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
CN1970547B (zh) 2006-12-07 2011-04-06 重庆医药工业研究院有限责任公司 非布司他的晶型及其制备方法
CN100546985C (zh) 2007-06-29 2009-10-07 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101412700B (zh) 2007-10-19 2011-06-08 上海医药工业研究院 非布司他的晶型及其制备方法
CN101386605B (zh) 2008-10-23 2010-09-08 中国科学院上海药物研究所 非布司他新型晶体及其制备方法

Also Published As

Publication number Publication date
EP2542540A1 (de) 2013-01-09
WO2011107911A1 (en) 2011-09-09
AU2011222462A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
JP7079527B2 (ja) 環内チアミジノアミド－アリールアミド系化合物及びｂ型肝炎を治療するためのその用途
CA2375017C (en) Hydrochloride of fused-heterocycle compound
CN109311832B (zh) 沃替西汀的帕莫酸盐及其晶型
WO2010083752A1 (zh) 一种高纯度的非布司他及其制备方法
CN109310674B (zh) 醛糖还原酶抑制剂及其使用方法
ES2889916T3 (es) Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
JP2000072773A (ja) プリン誘導体
ES2575000T3 (es) Proceso mejorado para la preparación de ambrisentano
AU2009215377A1 (en) Novel polymorphs and processes for their preparation
JP2007169288A (ja) レボフロキサシンおよびその形態の調製
WO2011101867A2 (en) Substantially pure salts of febuxostat and processes for preparation thereof
CA2480352A1 (en) Lansoprazole polymorphs and processes for preparation thereof
CA2792036A1 (en) Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
AU2012241378A1 (en) Febuxostat solid dispersion
CA1244431A (en) Phenylpiperazine derivatives and process for producing the same
WO2012098501A1 (en) Febuxostat co-crystals
US10385017B2 (en) Pyrrole compound, compositions and process for preparation thereof
WO2004089948A1 (en) Novel crystalline forms of ziprasidone hydrochloride
WO2011080651A2 (en) Polymorphic forms of febuxostat
CN1863799B (zh) 治疗糖尿病和脂质紊乱的色原烷羧酸衍生物
JP2001039976A (ja) 縮合複素環化合物の塩酸塩
KR101919642B1 (ko) 피페라진 유도체, 이를 제조하는 방법, 및 인슐린 저항성의 치료에서 이의 용도
AU2009286521A1 (en) Novel polymorphs of sunitinib and processes for their preparation
JP2002220336A (ja) 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
CA2566803A1 (en) Drying process for preparing crystalline solid famciclovir

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140225